Opioid-Induced Constipation Treatment Market Analysis Highlights Growth To $2.54 Billion By 2030 At 5.9% CAGR

The opioid-induced constipation treatment market is set to expand significantly as the demand for innovative therapies grows. Various factors, including rising opioid use and advances in targeted medications, are propelling this market toward promising prospects. Below, we explore the market size, key players, trends, and segmentation for a clearer understanding of its future trajectory.

Opioid-Induced Constipation Treatment Market Size and Growth Outlook
The market for opioid-induced constipation (OIC) treatments is projected to reach $2.54 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.9%. This steady expansion is driven by increasing prescriptions of opioids among aging populations, greater clinical emphasis on patient-centered pain management, and the broader availability of these treatments through online and retail pharmacies. Additionally, heightened investment in drugs targeting gastrointestinal disorders continues to support this upward trend. Key emerging market patterns include a growing preference for peripherally acting μ-opioid receptor antagonists (PAMORAs), targeted therapies that maintain pain relief while easing constipation, the adoption of combined pharmacological and non-pharmacological treatments, and a stronger focus on improving life quality for chronic pain sufferers.

The opioid-induced constipation treatment market size has grown strongly in recent years. It will grow from $1.9 billion in 2025 to $2.02 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to widespread opioid use for chronic pain management, limited effectiveness of traditional laxatives, growing prevalence of cancer-related pain, lack of early OIC-specific therapies, increasing hospitalization due to opioid side effects.

Download a free sample of the opioid-induced constipation treatment market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15881&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Important Factors Fuelling Opioid-Induced Constipation Treatment Demand
One major driver behind the market's growth is the increasing reliance on PAMORA-based therapies, which selectively target opioid receptors in the gut without diminishing the pain-relief effects of opioids. This precision reduces side effects and enhances patient compliance, making these therapies highly appealing in clinical settings.

Simultaneously, the rise in long-term opioid use, particularly among elderly patients managing chronic conditions, has created a substantial need for effective constipation treatments that do not compromise analgesia. Greater public awareness and improved diagnostic measures for opioid-induced constipation have also played a significant role in broadening the market.

View the full opioid-induced constipation treatment market report:
https://www.thebusinessresearchcompany.com/report/opioid-induced-constipation-treatment-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Leading Companies Making an Impact in the Opioid-Induced Constipation Treatment Market
Key players shaping this market include Pfizer Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Ironwood Pharmaceuticals Inc., Collegium Pharmaceutical Inc., Cumberland Pharmaceuticals Inc., RedHill Biopharma Ltd., Theravance Biopharma Inc., Mundipharma International Limited, Daiichi Sankyo Co Ltd, Progenics Pharmaceuticals Inc, Shionogi & Co Ltd, Purdue Pharma, Nektar Therapeutics, S L A Pharma AG, Bristol‐Myers Squibb Company, Fresenius Kabi AG, Viatris Inc, Novartis AG, Teva Pharmaceutical Industries Ltd, F Hoffmann‐La Roche Ltd, Aurobindo Pharma, Abbott Laboratories, and Daewoong Pharmaceutical Company.

In a notable development, Grünenthal GmbH, a Germany-based pharmaceutical company, completed a joint venture with Kyowa Kirin International in August 2023. This partnership covers 13 brands across six therapeutic areas with a strong emphasis on pain management, including medications for breakthrough cancer pain, opioid-induced constipation, and osteoporosis. Grünenthal holds a 51% majority stake in the venture and plans to acquire the remaining 49% by early 2026. Kyowa Kirin International, based in Japan, is also a key developer of OIC treatments, particularly peripherally acting mu-opioid receptor antagonists.

Current Trends Driving Innovation in the Opioid-Induced Constipation Treatment Market
Many companies are concentrating on the development of PAMORAs that offer targeted action on gut receptors to improve treatment efficacy and patient adherence while limiting systemic side effects during opioid use. These agents work by blocking μ-opioid receptors in the gastrointestinal tract without crossing the blood-brain barrier, thus preserving pain relief while addressing constipation at its root cause-a distinct advantage over traditional laxatives.

For example, in May 2025, Luye Pharma, a China-based firm, introduced Mimeixin, an oral sustained-release tablet combining oxycodone with naloxone. This once-daily medication manages pain effectively while counteracting opioid-induced constipation, offering patients better bowel regularity and fewer gastrointestinal side effects compared to older therapies. Mimeixin represents a convenient solution that merges analgesic and constipation management in a single dose.

Core Segmentation of the Global Opioid-Induced Constipation Treatment Market
This market can be broken down into several key segments:

1) Drug Class:
- Laxatives
- Peripherally Acting μ-opioid Receptor Antagonists
- Serotonin Receptor Agonists

2) Type of Administration:
- Oral
- Parenteral

3) Distribution Channels:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies

Further subcategories include:
- Laxatives: Osmotic, Stimulant, and Bulk-Forming types
- Peripherally Acting μ-Opioid Receptor Antagonists: Naloxegol, Methylnaltrexone, and Alvimopan
- Serotonin Receptor Agonists: Prucalopride and Tegaserod

Together, these classifications provide a comprehensive framework for analyzing the dynamic market and anticipating its future developments.

The 2026 edition of our market reports now delivers enhanced analytical coverage through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.